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Abstract 
 
Introduction: A range of impulse control disorders have been identified as possible behavioural 
effects of brain dopamine replacement therapy (DRT) in patients with Parkinson’s disease (PD).  
Among the behavioural problems associated with dysregulation of dopaminergic pathways 
underlying reward processing, hypersexuality carries significant social and legal repercussions, in 
addition to embarrassment for the patient with PD and his/her family. The present article evaluates 
the prevalence and characteristics of hypersexuality in the context of PD, focusing on the best 
available evidence. 
Methods: We conducted a systematic literature review according to the Prisma guidelines on large-
scale epidemiological studies (n>250) assessing hypersexuality in patients with PD treated with DRT. 
Results: Our systematic literature review identified 10 relevant studies characterised by medium–to-
large sample sizes (n=268-3,090). Average lifetime prevalence of hypersexuality in patients with PD 
on DRT was found to be 2.7% (7.4% in patients on dopamine agonists). In general, hypersexuality 
was associated with male gender and higher doses of dopamine agonists. Other clinically relevant 
associations included younger age, earlier PD onset and history of behavioural symptoms prior to 
dopamine agonist use.  
Conclusion: Hypersexuality is not rare in patients with PD treated with DRT, particularly in those on 
dopamine agonists. These findings indicate that PD specialists should regularly screen and monitor 
for hypersexuality, paying particular attention to younger male patients, with an early PD onset and 
previous history of behavioural problems. 
 
Key words: Parkinson’s disease; Hypersexuality; Impulse control disorders; Dopamine replacement 
therapy; Levodopa; Dopamine agonists. 
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1. Introduction 
 
Parkinson’s disease (PD) is increasingly recognised as a neuropsychiatric disorder characterised by 
both motor and non-motor clinical manifestations, encompassing autonomic, cognitive and 
behavioural symptoms [1]. Although behavioural problems may precede the onset of typical motor 
symptoms by years [2] and are important predictors of health-related quality of life in patients with 
PD [3-5], these symptoms are frequently unrecognised and undertreated. Over the last few years, 
the study of impulsivity in PD has been of particular interest, since it has been observed that 
dopamine replacement therapy (DRT) may lead to the development or worsening of specific impulse 
control disorders (ICDs),ranging from pathological gambling to compulsive shopping and punding [6]. 
ICDs are characterised by repetitive behaviours aimed at reward seeking [7] and occur in 
approximately 13.6% of patients with PD [8], suggesting that they are not a rare occurrence in 
specialist PD clinics. Specifically, hypersexuality was among the first PD-related ICDs to be 
recognised, since the early 1980s [9,10]. Hypersexuality can be clinically defined as “a preoccupation 
with sexual gratification outside the accepted social and personal bounds, despite the harm that 
may be incurred” [11]. It is often an underreported issue and has been demonstrated to be 
potentially problematic from both social and medico-legal perspectives for patients with PD and 
their families [12]. 
 
Compulsive sexual behaviour, including both pathological and conventional forms of sexual 
behaviour, has an estimated prevalence of 3.0% to 6.0% in the US adult population [13]. In PD, early 
prevalence estimates have shown considerable disparity, ranging from 1.7% to 8.8% [14-17]. 
However, most epidemiological studies have focussed on convenience samples of patients recruited 
at single sites, therefore providing limited evidence. In recent years, hypersexuality has been 
increasingly reported in association with hyperdopaminergic state in patients with PD; specifically, 
different studies have identified the association of hypersexuality with dopamine agonists [18,19] 
and levodopa treatment [8]. Approximately 2.2-8.3% of patients with PD taking Levodopa, 
Pramipexole, or Selegiline can develop hypersexuality according to preliminary studies [7,20-24].   
It is important that treating clinicians are aware of the extent of these pathological behaviours in the 
PD population and are able to correctly recognise them in order to implement appropriate 
management strategies and therefore limit potential harm to patients and society. Thus, we set out 
to conduct a systematic review focussing on the prevalence and clinical characteristics of 
hypersexuality in patients with idiopathic PD treated with DRT. 
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2. Methods 
 
We conducted a systematic literature review according to the methodology described in the PRISMA 
guidelines [25] to assess the prevalence and clinical characteristics of hypersexuality in patients with 
PD on DRT. Our searches were carried out across the Medline, Embase and PyscInfo databases using 
the search terms ‘Parkinson*’ and ‘hypersexual*’ with the latter being expanded, as appropriate, to 
include all related terms, such as ‘sexual deviation’, ‘erotomania’, ‘sexual addiction’ and 
‘psychosexual behaviours’.  
 
The searches were limited to original studies published in the English language since 1983. No limits 
were applied to the demographic characteristics of participants or the study type, in order to allow 
generalisation of the data to the entire PD population. We included only study on patients diagnosed 
with idiopathic PD and treated with any form of DRT.  Our review targeted studies with a sample size 
larger than 250 and excluded articles focussing solely on paraphilias, as these conditions do not 
necessarily accompany hypersexuality. The primary outcome measures were the point and/or 
lifetime prevalence of hypersexuality and the description of any clinical correlates for these patients. 
 
The selection process of this systematic literature review is illustrated by the flow chart in Figure 1.  
 
[PLEASE INSERT FIGURE 1 HERE] 
 
Titles and abstracts were initially reviewed; full texts were retrieved for all identified relevant articles 
and were then further assessed for possible inclusion. Finally, the reference lists of pertinent articles 
and the online Tables of Contents of relevant journals (including ‘Movement Disorders’, 
‘Parkinsonism and Related Disorders’, ‘Journal of Parkinson’s Disease’ and ‘Parkinson’s Disease’) 
were manually scanned to ensure that any other potentially relevant studies had not been missed 
out. After contacting the authors of unavailable material, it was found that three potentially eligible 
studies were conference abstracts with unpublished full texts and therefore had to be excluded from 
the present review.  
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3. Results 
 
3.1. Prevalence 
 
This systematic literature review identified six original studies on the prevalence of hypersexuality in 
PD that met our inclusion criteria. All were carried out since 2006 and took place in specialist centres 
for movement disorders, apart from two large postal surveys conducted in Scandinavia [26,27]. The 
main findings from these studies are summarised in Table 1.
 
[PLEASE INSERT TABLE 1 HERE] 
 
The study by Voon et al. [7] included a specifically designed questionnaire to screen for 
hypersexuality based on DSM-IV criteria. This questionnaire was to be completed by patients or their 
carer and consisted of five items assessing the possible links between increased sex drive and 
medication, preoccupation with sexual thoughts, inappropriate behaviour, use of explicit material 
and complaints by spouse. Additionally, diagnostic criteria for ‘pathologic hypersexuality’ were 
proposed focussing on the frequency and quality of these aberrant behaviours. This questionnaire 
has since been used in other studies investigating hypersexuality in PD. All pathological behaviours 
captured in the study by Voon et al. [7] had onset after starting dopaminergic medication. 
 
Weintraub et al. [24] used the Modified Minnesota Impulsive Disorders Interview (MIDI), which 
contains questions aimed at identifying various DSM-IV-defined ICDs, including clinically significant 
hypersexuality, in patients who screened positive for ICDs. This study used a screening process which 
was systematic yet unstructured and focussed on patients treated with Pramipexole, Ropinirole and 
Pergolide. 
 
Fan et al. [28] adopted Voon’s questionnaire (7) followed by telephone interview for patients who 
screening positive for increased sex drive.  Hypersexuality was the most common ICD identified in 
this study, with 6 patients reported as fulfilling diagnostic criteria for pathological hypersexuality.  All 
of these patients were being treated with Piribedil; five were also on Levodopa and one on 
Pramipexole. 
 
Weintraub et al. [8] conducted a large case-control study on 3,090 patients (of whom 98.1% were 
taking either levodopa or dopamine agonists) to assess the point prevalence of ICDs, including 
hypersexuality. 
 
Hassan et al. [29] investigated the frequency of ICDs by retrospectively assessing the medical records 
of all patients on DA therapy in a specialist PD clinic. With regard to DA doses, 64.0% of patients 
reached the defined therapeutic dosage and 33.0% reached the defined target dose. The authors of 
this study defined sexual behaviours as pathological in line with the DSM-IV-TR definition of “failure 
to resist […] despite severe personal, family, or vocational consequences” [11]. 
 
Chiang et al. [30] employed Voon’s criteria [7] for hypersexuality and found the highest lifetime 
prevalence of hypersexuality (3.0%) among the reviewed studies which used this set of diagnostic 
criteria.  
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In the Scandinavian surveys [26,27] and the large single-centre study conducted in Italy [31] and 
Mexico [32], the frequency of ICDs was assessed using the Questionnaire for Impulsive-Compulsive 
Disorders in Parkinson’s Disease (QUIP), a self-administered screening questionnaire for ICDs and 
other compulsive behaviours in PD [33]. In the two single-centre studies, the QUIP was 
complemented by diagnostic interviews [31,32]. 
 
 
3.2. Relationship to drug therapy 
 
All studies found a significantly increased risk of developing hypersexuality and other ICDs with the 
use of DAs. When comparing patients on DAs and patients not on DAs, Weintraub et al. [8] found 
that the frequency of hypersexuality was significantly different: 90.0% versus 18.0%; OR 2.59 (CI 1.6-
4.3; p<0.001). Both Weintraub et al. [8] and Hassan et al. [27] reported that a combination of DA and 
Levodopa further increased the odds of having an ICD compared to DAs alone by 50.0% [8], although 
individually DAs were more causative [7]. 
 
 
3.3. Clinical characteristics  
 
The study by Weintraub et al. [8] found that men were more likely than women to be diagnosed 
with compulsive sexual behaviour (5.2% vs. 0.5%; OR, 11.98; CI, 4.87-29.48; p<0.001). These findings 
were in line with the results of the studies by Voon et al. [7] and Chiang et al. [28], which reflect 
gender patterns in the general population [13,29,30]. Voon et al. [7] also found that 6 of the 7 
patients diagnosed with hypersexuality had co-morbid depression and that hypersexuality was 
associated with early PD onset (p<0.001). A univariate analysis carried out by Weintraub et al. [24] 
found that younger age, longer PD duration, history of ICD symptoms prior to PD diagnosis and use 
of DAs or Amantadine were associated with the presence of an active ICD. After using a multivariate 
model, these authors showed that DA use (p=0.01) and history of ICD symptoms prior to PD onset 
(p=0.02) were the only significant predictors of an active ICD. Fan et al. [26] found that alcohol 
consumption was an independent risk factor for ICD in the Chinese population. Living in the US, 
being unmarried and current cigarette smoking were additional demographic variables 
independently associated with ICDs according to the findings of the study by Weintraub et al. [8]. 
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4. Discussion 
 
4.1. Prevalence and demographic characteristics 
 
This systematic literature review set out to determine the prevalence of hypersexuality in patients 
with idiopathic PD treated with DRT and to assess the clinical characteristics associated with 
hypersexuality in the largest studies conducted to date. The combined results of the six identified 
studies indicate an average lifetime prevalence of hypersexuality of 2.7% (7.4% in patients on DAs). 
Based on the results of three studies, the average active prevalence of hypersexuality was also 2.7%. 
The higher prevalence estimates for risk of both ICDs and hypersexuality in the Scandinavian studies 
[26,27] are not prevalence rates of clinical diagnosis, because these postal surveys relied solely on a 
self-report instrument (QUIP) which also identifies subclinical syndromes. In addition to male 
gender, younger age has been associated with ICDs in the general population. The study by 
Weintraub et al. [8] confirmed these observations by showing that the age effect remained even 
after controlling for DA exposure. However this association may also reflect differences in 
prescribing patterns, since younger patients are more likely to be prescribed a dopamine agonist 
[8,24,29]. Finally it has been argued that although younger patients may be inherently more 
susceptible ICDs, they may also be better able to act on their impulses than older patients [29]. 
 
 
4.2. Clinical phenomenology 
 
Apart from touching on the use of pornography, the prevalence studies included in the present 
review did not formally discuss the clinical phenomenology of hypersexuality in PD, which has been 
mainly reported in single case reports or case series [18,21,34-36]. Reported hypersexual behaviours 
encompass excessive masturbation, compulsive pornography use, extramarital affairs, and plain 
increased libido. A recently published systematic literature review with focus on the clinical 
manifestations of paraphilias or paraphilic disorders in PD identified 22 case reports on a total of 31 
patients [37]. These reports mainly described middle-aged male patients with motor complications, 
young age at PD onset, and long disease duration, reporting a range of altered sexual behaviours 
concomitant to either initiation or dose escalation of different forms of DRT (the majority being 
DAs). Exhibitionism was the most commonly described paraphilia, followed by transvestism, 
zoophilia, voyeurism, and pedophilia. Of note, both hypersexual behaviours and paraphilias were 
commonly reported in association with other ICDs, including pathological gambling, delusional 
jealousy, hyperphagia and other repetitive behaviours, such as compulsively sweeping or playing 
video games. 
 
 
4.3. Role of dopaminergic stimulation 
 
The causative role of dopaminergic medications was established by the concordant findings of the 
reviewed studies: Voon et al. [7] clearly showed that all behaviours had onset after medication onset 
and none of the patients had excessive medication use, and Weintraub et al. [24] found that all 
patients were taking DAs (Pramipexole, Ropinirole, or Pergolide) while symptomatic. Interestingly, 
almost one-third (30.0%) of patients had developed pathological behaviours at target doses of drugs. 
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The findings of the reviewed studies demonstrated a strong class association [24,38-40], but no 
statistically significant correlation with individual DA type or dose. Weintraub et al. [24] found that 
daily doses of DAs were higher for those screening positive for ICDs when concerning Pergolide, but 
not Pramipexole or Ropinirole. Weintraub et al. [8] also reported an independent, dose-dependent 
association of Levodopa therapy and active ICDs. The Levodopa monotherapy effect had previously 
been suggested by other authors [18] and was supported by the results of the study by Voon et al. 
[7], although its significance was questioned because of the limited sample size. 
 
Of note, the only study [26] which reported no difference between agonist and nonagonist 
treatment groups in ICD risk was conducted after the role of DAs in compulsive behaviours had 
become apparent to the scientific community, and the clinical practice might have changed 
regarding the optimal treatment of patients with early PD. Indeed, a number of patients might not 
have been given DAs because they had been considered at risk for developing ICDs and the daily 
doses of DAs in this sample were small compared to the doses used by other studies. 
 
Patients with ICDs often report being psychologically driven to engage in rewarding behaviours [29]. 
There is evidence of a distinct mechanism of action, as opposed to an additive effect, for DAs in the 
development of ICDs. A possible neurophysiological explanation revolves around dopamine-receptor 
binding profiles [8]. Dopamine 1 (D1) and D2 receptors, which are abundant in the dorsal striatum 
[41], are thought to mediate the motor effects of dopamine replacement therapies. In contrast, D3 
receptors are abundant in the ventral striatum [41], a region associated with both behavioural 
addictions [42] and substance abuse disorders [43]. Second generation non-ergot DAs, such as 
Pramipexole and Ropinirole, demonstrate higher selective affinity for D3 receptors [44] compared to 
D1 and D2 receptors [44]. The less robust association between ICDs and Levodopa could reflect the 
fact that its physiologically active metabolite dopamine shows greater selectivity to D1 and D2 
receptors [44]. Overall, behavioural changes in patients with PD appear to be associated with 
abnormal dopamine stimulation caused by a combination of disease progression, dopaminergic 
medications and environmental and genetic factors [1]. There is high inter-individual variability in 
the predisposition to develop impulsive behaviours, with genetic burden, character traits and pre-
morbid mental state all playing a part [35,45]. 
 
The pharmacological approach for patients experiencing ICDs in the context of hyperdopaminergic 
treatment is simply dose reduction, discontinuing or switching the DA [9]. Hassan et al. [29] found 
that following cessation or dose reduction of the DA, almost all patients had complete or partial 
resolution of their compulsive behaviours at follow-up. Weintraub et al. [24] found similar results, 
with 7/18 patients becoming completely asymptomatic with the recommended changes in 
pharmacotherapy, further suggesting that impulsive behaviours are time-locked to dopamine 
agonist use. It is important to reach an agreement with the patient and his/her family about the 
optimal compromise between motor benefits and non-motor adverse effects resulting from DA 
pharmacotherapy. Thus, sound clinical judgement is crucial and close monitoring is required, 
particularly when initiating and titrating medication [9]. 
 
 
4.4. Ascertainment of sexual behaviours 
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In consideration of the lack of a standardised set of diagnostic criteria for hypersexuality, clinical 
researchers have used a pragmatic approach based on the use of questionnaires encompassing a 
range of hypersexual behaviours. One of the main problems with the commonly used questionnaire 
approach is under-ascertainment of prevalence. This approach may fail to capture patients who are 
reluctant to disclose sensitive behaviours of sexual nature due to associated stigma, shame and 
embarrassment, as well as possible legal implications. Not surprisingly, it has been found that 
behaviours are often reported by the patient’s partner, after initial denial by the patient [29]. Indeed 
spousal assistance may be deemed crucial in providing a collateral history, although this in itself may 
introduce a bias in terms of accuracies and insight. Patients with PD and cognitive problems are at 
particularly high risk of returning either inaccurately or inadequately completed questionnaires. 
Moreover, questionnaires alone do not allow for a reliable differential diagnosis between behaviours 
which are clearly excessive and pathological and behaviours which could represent benign variants 
of accepted sexuality. The importance of a thorough clinical assessment cannot be underestimated. 
Studies conducted by mail and telephone interview [24, 29] may not pick up or assess conditions 
such as depression, anxiety and diminished cognitive function that are likely to confound the results 
of self-reports [29]. The accuracy of screening instruments for the detection of neuropsychiatric 
disorders in patients with PD was recently reviewed [46] and the Parkinson’s Disease-Sexual 
Addiction Screening Test (PD-SAST) [47] was found to be a valid instrument for hypersexuality 
specifically. The PD-SAST is a short (5-item) and reliable measure of hypersexuality that was 
developed and validated in 2013 to be used in everyday practice in patients with PD as a screening 
instrument for multidimensional aspects of hypersexuality [47]. 
 
A common problem with the studies on hypersexuality in PD is loss to follow up: for example, in the 
study by Voon et al. [7], 4 patients with hypersexuality could not be reached, 14 patients 
misinterpreted the questionnaire and 2 patients with likely hypersexuality refused assessment. 
Similarly, Fan et al. [28] found that 12 patients screening positive for ICDs refused a telephone 
interview. Another factor making hypersexuality difficult to diagnose is the inter-individual variability 
which characterises the sex life. Changes from baseline sexual behaviours may not be regarded as 
abnormal even in the presence of a clear deviation from the patient’s habitual behaviour. Likewise, 
patients with excessive sexual thoughts who deny distress or interference with their daily life may be 
diagnosed as ‘subclinical’ and therefore not captured in epidemiological studies. In general, 
prevalence rates may have been influenced by differences in culture and ethnicity, social and 
environmental factors and medication practices (both dosage and types of drugs used) across 
different centres. For example, the relatively lower frequency of ICD behaviours in China may reflect 
less widespread use of Levodopa and DAs (45.8% in the Chinese population versus 50.4-68.0% in 
Western Countries) [24,28,48,49]. 
 
 
4.5. Limitations 
 
There are several limitations to consider when appraising the results of our review. Despite the 
efforts made, coverage of relevant literature could be incomplete. Extensive hand-searching of 
further scientific journals and translations of foreign material may have yielded additional studies. 
Moreover, our search strategy did not capture unpublished material, resulting in publication bias. 
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Finally, there was heterogeneity in the methodology of the reviewed epidemiological studies, with 
some studies assessing point prevalence and others focusing on lifetime prevalence: the cumulative 
lifetime prevalence of hypersexuality in PD is likely to be higher than point prevalence estimates. The 
overall quality of the studies varied depending on both assessment methods and setting/target 
population. It is important to note that patients were recruited from specialist centres located in 
selected regions, thus limiting the generalisability of any findings: movement disorder referral 
centres are likely to have higher rate of DA use as compared to general neurology clinics or district 
hospitals. The fact that the total number of hypersexuality cases identified across the reviewed 
studies was relatively small further limited any conclusions about the exact nature of the association 
between DA treatment and ICDs in PD.  
 
Although prospective studies are considered most ideal to study any causative role of DRT, they may 
not be feasible due to fact that PD patients frequently undergo changes in medication over time and 
that there may be a significant lag time between initiation of DRT and onset of ICD behaviours [8]. 
Ideally, multicentre studies involving larger random samples of patients, with established diagnostic 
and inclusion criteria are needed to definitively determine the prevalence and clinical correlates of 
ICDs in PD. 
 
 
4.6. Conclusions 
 
The results of this literature review show that hypersexuality is not rare in patients with PD treated 
with DRT, particularly in those taking DAs. It has been shown that hypersexual behaviours and ICDs 
in general are an under-reported phenomenon in the PD population: for example, in the study by 
Weintraub et al. [24], the problem was only documented in 27.3% of patients with an active ICDs. 
These findings indicate that PD specialists should regularly screen and monitor for hypersexuality, 
paying particular attention to younger male patients, with an early PD onset and previous history of 
behavioural problems. Those patients shown to have an increased risk should be screened and it is 
paramount that they are educated on the risk of developing such pathological behaviours as 
potential side effects of their medication. Since patients are unlikely to volunteer their symptoms 
[50], it is important for the physician to recognise the early manifestations of hypersexuality, in 
order to diagnose and manage the patients accordingly before harm is brought upon relationships 
and the law [51]. This will help prevent the significant psychosocial implications hypersexuality 
carries for patients with PD and their families. There is a need for further investigations into 
hypersexuality and other ICDs as adverse behavioural effects of deep brain stimulation in patients 
with PD who underwent this increasingly common procedure [52]. Finally, as DAs are increasingly 
being used for other indications (restless legs syndrome and other neuropsychiatric conditions), it is 
important for future research to assess the prevalence and risk of hypersexuality in other clinical 
populations treated with dopaminergic agents. 
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Table 1. Studies on the prevalence of hypersexuality in Parkinson’s disease (PD). 
 
Figure 1. Selection process for the studies on hypersexuality In Parkinson’s disease included in this 
systematic literature review. 
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Table 1: Studies on the prevalence of hypersexuality in Parkinson’s disease (PD). 
 
Study Voon et al. (7) Weintraub et al. (24)  Fan et al. (28) Weintraub et al. (8) Hassan et al. (29) Chiang et al. (30) Joutsa et al. (26) Poletti et al. (31) Rodríguez-Violante et 
al. (32) 
Callesen et al. (27) 
Year  2006 2006 2009 2010 2011 2011 2012 2013 2014 2014 
Setting Outpatient clinic, 
movement 
disorders centre, 
Canada 
Two university-based 
movement disorder 
centres, Philadelphia, 
USA 
Centre of 
neurodegenerative 
disorders, Xuanwu 
Hospital, China 
46 movement 
disorder centres in 
the United States 
and Canada 
Mayo clinic, USA Outpatient clinic, 
Taiwan 
Postal survey of 
members of the 
Finnish Parkinson 
Association, Finalnd 
Movement disorders 
outpatient clinic, 
Viareggio, Italy 
Movement Disorders 
Clinic at the Neurology 
and Neurosurgery 
National Institute in 
Mexico City, Mexico 
Postal survey of 
outpatients  identified 
through the Danish 
National Patient 
Registry, Denmark 
Study population 293 of 396 
(75.0%) 
consecutive 
patients with PD 
272 patients with PD. 
Active prevalence of 
ICDs  4.0%; lifetime 
prevalence of ICDs 
6.6% 
312 of 400 (78.0%) 
patients with PD on 
medication. Lifetime 
prevalence of ICDs 
3.5% 
3090 patients with 
PD. Active 
prevalence of ICDs 
13.6% 
321 patients with PD on 
dopamine agonists. 
Lifetime prevalence of 
compulsive behaviours 
22% (of whom 16% 
defined as ‘pathologic’) 
268 of 278 (96.4%) 
consecutive patients 
with PD. Lifetime 
prevalence of ICDs 
5.6% 
575 of 1000 (57.5%) 
patients with PD 
(stratified random 
sample from the 
patient register). 
Lifetime prevalence 
of ICDs 34.8% 
805 consecutive 
patients with PD. 
Lifetime prevalence 
of ICDs 8.1% 
300 consecutive 
patients with PD. 
Lifetime prevalence of 
ICDs 10.6% 
490 patients with PD. 
Active prevalence of 
ICDs  14.9%; lifetime 
prevalence of ICDs 
35.9% 
Type of study Case-control Cross-sectional Case-control Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cross-sectional Case-control Cross-sectional 
Study duration 
(months) 
3  11  - 6  24 3 9 17 - - 
Relevant 
inclusion/exclusion 
criteria 
Excluded patients 
with atypical 
parkinsonism, 
cognitive 
impairment, and 
≤1 year motor 
symptom onset 
Excluded patients 
with  secondary 
parkinsonism and 
cognitive impairment 
Excluded patients 
with atypical 
parkinsonism, 
secondary 
parkinsonism, and 
cognitive 
impairment 
Included patients on  
medication for ≤1 
year with a 
demonstrated 
response (DA 
treatment not 
initiated or 
terminated in prior 6 
months). 
 
Included patients with 
idiopathic PD on 
Ropinirole/Pramipexole 
for ≥3 months and seen 
at least once by specialist 
in clinic during the study 
period 
Excluded patients  
with cognitive 
impairment 
Excluded patients 
reporting other 
primary diagnoses 
and patients without 
appropriate 
medication 
data 
Excluded patients 
with newly 
diagnosed drug-
naïve Parkinson’s 
disease and patients 
with  secondary or 
atypical 
Parkinsonism 
Included only patients 
belonging to level 1 
and 2 (average 
household 
income of 500 
USD/monthly or lower 
and no social security) 
Excluded patients with 
a diagnosis of 
dementia or other 
neurological or 
neurodegenerative 
disease (including 
atypical PD and 
Parkinson plus), 
patients with previous 
history of strokes or 
brain tumors, and 
patients with 
personality disorders 
Assessment Questionnaire,  
psychiatric 
assessment  
Minnesota Impulsive 
Disorders Interview 
(MIDI) 
 
Questionnaire, 
telephone interview. 
Voon’s criteria for 
hypersexuality 
Minnesota Impulsive 
Disorders Interview 
(MIDI) 
Assessment based on 
DSM-IV criteria 
Questionnaire,  
psychiatric 
assessment. Voon’s 
criteria for 
hypersexuality 
Questionnaire 
for Impulsive-
Compulsive 
Disorders in 
Parkinson’s Disease 
(QUIP) 
Questionnaire 
for Impulsive-
Compulsive 
Disorders in 
Parkinson’s Disease 
(QUIP) followed by 
semistructured 
diagnostic interview 
Structured interview 
(Minnesota Impulsive 
Disorders Interview 
(MIDI), assessment 
based on DSM-IV 
criteria), neurological 
evaluation,  
Questionnaire 
for Impulsive-
Compulsive Disorders 
in Parkinson’s Disease 
(QUIP) 
Questionnaire 
for Impulsive-
Compulsive Disorders 
in Parkinson’s Disease 
(QUIP) 
Active prevalence 2.0% 2.6% - 3.5% - - - - - - 
Lifetime prevalence 2.4% 2.6% 1.9% - - 3.0% 22.8% 3.0% 3.0% 9.0% 
Lifetime prevalence 
on DAs 
7.2% - - - 7.5% - - - - - 
Main strengths  Systematic 
screening using 
set criteria, 
Use of multivariate 
model to determine 
predictors of active 
High response rate, 
controlled study 
Systematic 
screening, large 
sample size, blinding 
Large recruitment 
window, multi-level 
assessment of compulsive 
Limited referral bias Large sample size, 
not limited to 
specialist clinics 
Two-stage 
assessment, large 
sample size from 
Multi-stage assessment Large sample size, not 
limited to specialist 
clinics 
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controlled study   ICDs of raters behaviours single centre 
Main limitations Referral bias Referral bias, lack of 
structured diagnostic 
interviews, long 
interval between 
screening and follow-
up 
Potential 
heterogeneity across 
research sites 
Referral bias, lack of 
structured 
diagnostic 
interviews 
Referral bias, small 
assessment window 
Loose 
inclusion/exclusion 
criteria 
Sample derived, 
from PD association 
(support group) 
rather than general 
community, no 
physician 
verification of PD 
diagnosis, self-report 
tool which also 
identifies subclinical 
syndromes 
Referral bias, 
underdetection of 
impulse control 
disorders in 
cognitively 
preserved patients 
Cross-sectional design, 
population with a low 
socio-economic level 
from a single tertiary 
medical centre 
Sample derived, from 
PD registry rather than 
general community, no 
physician verification 
of PD diagnosis, self-
report tool which also 
identifies subclinical 
syndromes 
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Highlights 
 
- Patients with Parkinson’s disease (PD) on pharmacotherapy can develop hypersexuality 
 
- Hypersexuality has social and legal repercussions for the patients and their families 
 
- We conducted a systematic literature review on the prevalence of hypersexuality in PD 
 
- Data from 8 large studies (n=268-3,090) yielded a lifetime prevalence figure of 2.7%  
 
- Hypersexuality was associated with male gender and higher doses of dopamine agonists 
 
 
